Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Worldwide Recall On Allergan Textured Breast Implants

Executive Summary

Allergan PLC announced that it would take its Biocell textured breast implants and tissue expanders off the market worldwide shortly after the US FDA released additional information linking the use of the implants to a rare cancer.

You may also be interested in...



Judge OKs Class-Action Suit From Allergan Investors

The lawsuit says that Allergan repeatedly downplayed the cancer risk its textured breast implants posed as compared to those from other manufacturers.

FDA: 36 Dead From Breast Implant-Associated Lymphoma Since 2019, Hundreds Sickened

The US FDA reports the numbers on women globally who've died or been sickened by two types of breast implant illnesses.

FDA Issues Warning Letters To Breast Implant Makers Allergan And Ideal Implant

The US agency warned Allergan about failing to meet postmarket study requirements and Ideal Implant about Quality System Regulation violations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel